Alteogen Announces Completion of Phase 1 Clinical Trial of Aflibercept Biosimilar in Wet AMD Patients

First clinical trial of Aflibercept biosimilar to be completed in Korea Supported by global formulation and process patents   DAEJEON, South Korea--(BUSINESS WIRE)--#196170KQ--Alteogen Inc. (KOSDAQ:196170) announced that it has completed Phase 1 ...

Full "IntellAsia: Resources" article